Brychs Milagros Roque-Pumahuanca

Brychs Milagros Roque-Pumahuanca

Auto-generated profile, based on publicly available information

Brychs Milagros Roque-Pumahuanca

Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022
Verified
Report
Closed access
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
LMLaura Yesenia Machaca-Luque
Laura Yesenia Machaca-Luque
BRBrychs Milagros Roque-Pumahuanca
Brychs Milagros Roque-Pumahuanca
ALEXSANDRO SOBREIRA GALDINOALEXSANDRO SOBREIRA GALDINO
ALEXSANDRO SOBREIRA GALDINO
RODOLFO CORDEIRO GIUNCHETTIRODOLFO CORDEIRO GIUNCHETTI
RODOLFO CORDEIRO GIUNCHETTI
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Review question / Objective: The objective of the current work is to systematically review and summarize the available literature on the diagnostic accuracy of diagnostic tests for Chagas Disease. Eligibility criteria: The studies were selected in three stages. In the first, non-English language articles, duplicate articles, reviews, and meta-analyses were excluded, only articles published after 1990 and conducted on humans were included. In the second stage, the titles and ab-stracts of the articles selected through the search strategy were examined. Finally, the highly relevant full studies were retrieved and separated from the articles with a title or abstract that did not provide sufficient data to be included.

14 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
BRBrychs Milagros Roque-Pumahuanca
Brychs Milagros Roque-Pumahuanca
LMLaura Yesenia Machaca-Luque
Laura Yesenia Machaca-Luque
LPLeydi Pola-Romero
Leydi Pola-Romero
ALEXSANDRO SOBREIRA GALDINOALEXSANDRO SOBREIRA GALDINO
ALEXSANDRO SOBREIRA GALDINO
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Background: Leishmaniasis constitutes a serious global public health concern. It is a complex parasitic disease characterized by a spectrum of clinical forms with varying severity, driven by host immune responses and immunopathology. Its accurate diagnosis is essential for guiding timely treatment. Yet, diagnosing leishmaniasis is challenging and requires a combination of tests. Methodology/Principal findings: We conducted a systematic review and meta-analysis to evaluate the applicability and diagnostic accuracy of molecular and immunological tests for the laboratory diagnosis of human tegumentary leishmaniasis (TL) and visceral leishmaniasis (VL). We searched the PubMed database for studies published between 1990 and 2021 on leishmaniasis diagnosis. Following PRISMA statement recommendations, we included 165 publications that met the selection criteria. Among the evaluated tests, polymerase chain reaction (PCR)-based tests showed good diagnostic performance, with area under the curve values (restricted to observed FPRs, AUC FPR ) of 0.919 and 0.965 for the diagnosis of TL and VL, respectively. For TL, serological tests showed median sensitivities ranging from 83.3% to 88.1% and median specificities ranging from 82.0% to 92.4%, whereas the leishmanin (Montenegro) skin test had a median sensitivity of 91.7% and a median specificity of 83.4%. For VL, the direct agglutination test (DAT) and enzyme-linked immunosorbent assay (ELISA) exhibited higher sensitivity (median 93.0-93.8%) than rapid diagnostic tests (RDT, 89.1%) and the immunofluorescence antibody test (IFAT, 82.0%). These four tests displayed high specificity (median 95.5-96.9%). DAT showed comparable performance to molecular tests, with an AUC FPR of 0.966. Conclusions/Significance: Molecular tests exhibited high accuracy in diagnosing tegumentary and visceral leishmaniasis. Nevertheless, these tests have yet to be incorporated into routine clinical practice in endemic regions, as they still require specialized technical expertise and robust laboratory infrastructure. We advocate for the development and implementation of diagnostic procedures tailored to the needs of each endemic setting, considering local contexts and available resources, wherein molecular tests could facilitate early, accurate diagnosis of leishmaniasis. Author Summary: Leishmaniasis remains a significant global public health challenge, with millions of people at risk of infection, particularly in rural areas of tropical and subtropical regions. This parasitic disease presents with diverse clinical forms, ranging from skin ulcers to life-threatening mucosal or visceral organ damage. Early and accurate diagnosis of leishmaniasis is critical for timely treatment, in turn impacting disease control. Diagnosing leishmaniasis requires reliable laboratory tests. This work is a comprehensive systematic review and meta-analysis to evaluate the diagnostic accuracy of widely used molecular and immunological tests for human leishmaniasis, focusing on both tegumentary and visceral forms. Our findings reveal that PCR-based molecular tests enable highly accurate diagnosis of all forms of leishmaniasis, outperforming serological tests in many instances. Despite this, their use in endemic regions remains limited due to the need for specialized equipment and trained personnel. We emphasize the performance of immunological tests, such as DAT, LST, and ELISA, which are used in clinical and research settings and can serve as a diagnostic complement in resource-limited settings. Ultimately, this work underscores the importance of developing tailored diagnostic algorithms that incorporate molecular tests alongside simpler, field-friendly diagnostic tools to improve early diagnosis of leishmaniasis and patient outcomes in diverse epidemiological contexts.

4 September 2022 in medRxiv
Verified
Preprint
Open access
PDF file
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
LLLaura Yesenia Machaca Luque
Laura Yesenia Machaca Luque
BPBrychs Milagros Roque Pumahuanca
Brychs Milagros Roque Pumahuanca
ALEXSANDRO SOBREIRA GALDINOALEXSANDRO SOBREIRA GALDINO
ALEXSANDRO SOBREIRA GALDINO
RODOLFO CORDEIRO GIUNCHETTIRODOLFO CORDEIRO GIUNCHETTI
RODOLFO CORDEIRO GIUNCHETTI
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
The present systematic review and meta-analysis about the accuracy of diagnostic tests aim to describe the findings of literature over the last thirty years for the diagnosis of Chagas disease (CD). This work aimed to determine the accuracy of diagnostic techniques for CD in the disease’s acute and chronic phases. The PubMed database was searched for studies published between 1990 and 2021 on CD diagnostic. Fifty-six published studies that met the criteria were analyzed and included in the meta-analysis, evaluating diagnostic accuracy through sensitivity and specificity. For Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescent Antibody Technique (IFAT), Hemagglutination Test (HmT), Polymerase Chain Reaction (PCR) and (Real-Time Polymerase Chain Reaction qPCR diagnosis methods, the sensitivity had a median of 99.0%, 78.0%, 75.0%, 76.0% and 94.0%, respectively; while specificity presented a median of 99.0%, 99.0%, 99.0%, 98.0% and 98.0%, respectively. This meta-analysis showed that ELISA and qPCR techniques had a higher performance compared to other methods of diagnosing CD in the chronic and acute phases, respectively. It was concluded by means of the AUC restricted to the false positive rates, that the ELISA diagnostic test presents the highest performance in diagnosing acute and chronic CD, compared to serological and molecular tests. Future studies focusing on new CD diagnostics approaches should be targeted.

20 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLaura Yesenia Machaca-Luque
Laura Yesenia Machaca-Luque
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
BRBrychs Milagros Roque-Pumahuanca
Brychs Milagros Roque-Pumahuanca
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Chagas disease (CD) is a neglected tropical disease endemic to Latin America and has emerged as a global health concern due to the migration of infected individuals. With its epidemiological complexity, difficulty in obtaining appropriate diagnoses, and poor treatment, the search for novel therapeutic options remains. In this context, we conducted a systematic review and meta-analysis of preclinical studies employing animal models to verify the progress in CD treatment. We searched the PubMed database for CD treatment studies published between 1990 and 2023, adhering to the PRISMA guidelines. Twelve papers met the inclusion criteria. The findings indicate that the fifteen treatment alternatives examined, mainly between 2010 and 2014, demonstrated efficacy in experimental CD models, evidenced by significant parasitemia reduction. Bis-triazole DO870 and VNI were effective in the acute and chronic phases, respectively. However, of these emerging therapies, only posaconazole and fexinidazole have progressed to clinical trials, yielding unsatisfactory outcomes as CD monotherapies. This meta-analysis highlights the existence of promising new drug candidates for CD treatment, but most remain in the preclinical stages. Those that reached clinical trials did not demonstrate optimal results, underscoring the ongoing challenges in CD therapy. Collaborative efforts among the academic community, pharmaceutical industries, funding agencies, and government agencies are urgently needed to accelerate the development of more effective medications against CD.

16 November 2023
Verified
Report
Closed access
BRBrychs Milagros Roque-Pumahuanca
Brychs Milagros Roque-Pumahuanca
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
LMLaura Yesenia Machaca-Luque
Laura Yesenia Machaca-Luque
LPLeydi Pola-Romero
Leydi Pola-Romero
Vanessa AdauiVanessa Adaui
Vanessa Adaui
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
INPLASY2023110066 The diagnostic accuracy of laboratory tests for human leishmaniasis: a systematic review and meta-analysis Keywords: Leishmaniasis; sensitivity; specificity; diagnostic accuracy; …

25 March 2024
Verified
Report
Closed access
LLLaura Yesenia Machaca Luque
Laura Yesenia Machaca Luque
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
BRBrychs Milagros Roque-Pumahuanca
Brychs Milagros Roque-Pumahuanca
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
INPLASY202430101 Treatment options for Chagas Disease: a systematic review and meta-analysis preclinical studies with animal models Keywords: Chagas disease; treatment; efficacy; systematic review;…